Skip to content
Screener

Crinetics Pharmaceuticals CRNX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
-$24.41M-2.2%
XER
Xeris Biopharma Holdings, Inc.XERS
-$31.09M-1,513%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$159.56M-254%
Immunome logo
ImmunomeIMNM
-$73.46M-69.2%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.92B+246%
Enterprise value$8.85B+244%
P/S493.7×-1,359×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Net loss per share:
Net loss per share — basic and diluted$(1.23)$(1.04)
Weighted average shares — basic and diluted104,09993,102
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities$(3,147)$1,033
Unrealized gain on foreign currency286
Total other comprehensive income (loss)(3,119)1,039
Comprehensive loss$(130,964)$(95,735)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Crinetics Pharmaceuticals (CRNX) reported comprehensive income (loss), net of tax, attributable to parent of -$130.96M in Q1 2026.
How has Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent decreased by 36.8% year-over-year, from -$95.74M to -$130.96M.
What is the long-term trend for Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent has grown at a 44.0% compound annual growth rate (CAGR), from -$108.05M to -$464.42M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This is the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. It provides a comprehensive view of the company's total financial performance and changes in net worth beyond standard net earnings. It is a critical measure for assessing the overall economic impact of all financial activities on shareholder value.

Ask your AI about Crinetics Pharmaceuticals's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude